NCT06278285Recruiting
Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
Normalizing weight gain and preventing the redistribution of body fat is a major health issue, and could help prevent the onset of various symptoms of metabolic syndrome. Above all, it is important to understand the mechanisms by which these different treatments affect adipose tissue. To this end, the investigators will first study the impact of GLP-1 analogues on adipose tissue. The main objective is to show that subjects treated with a GLP-1 agonist have a significant change in their oxytocin levels compared with subjects not treated with a GLP-1 agonist.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 9 Feb 2024
- Start date
- 6 Mar 2024
- Primary completion date
- 6 Sept 2026
- Lead sponsor
- Centre Hospitalier Universitaire de Nice
- Diseases
- Obesity
- NCT number
- NCT06278285
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 6 Mar 2024 to the primary completion date, 6 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Pregnant or breast-feeding women.
- Vulnerable patients (under guardianship)
- Patients deprived of liberty
Who the study is looking for
- Patient over 18 years of age.
- Patient able to read and understand the information/consent leaflet.
- Patient with BMI \> 35 with at least one comorbidity. Or BMI \> 40
- Indication for digestive surgery validated in a multidisciplinary consultation meeting and prior agreement accepted by the CPAM.
- Membership of a social security scheme
- Patient's signed informed consent
- For subjects in the GLP-1 analogue group: GLP-1 analogue taken for at least 3 months.
- For non-GLP-1 analogue group: never taken GLP-1 analogues.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chu de Nice Hopital de L'Archet Coordinator of this site? Confirm its status | Nice | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.